ProfileGDS5678 / 1419798_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 66% 60% 56% 59% 62% 52% 59% 60% 62% 60% 60% 59% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6042959
GSM967853U87-EV human glioblastoma xenograft - Control 23.9827566
GSM967854U87-EV human glioblastoma xenograft - Control 33.5978860
GSM967855U87-EV human glioblastoma xenograft - Control 43.3637956
GSM967856U87-EV human glioblastoma xenograft - Control 53.4993359
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8087662
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3374652
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5613159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5704160
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6732462
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.587360
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5712560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.55359
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7595263